Baker Bros. Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

Baker Bros. Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-804,720	Closed	-$48.2M	–	116
2019 Q4	$48.2M	Sell	804,720 -701,718	-47%	-$26.3M	0.26%	29
2019 Q3	$42.3M	Hold	1,506,438	–	–	0.29%	29
2019 Q2	$57M	Sell	1,506,438 -208,745	-12%	-$8.02M	0.39%	26
2019 Q1	$66.9M	Buy	1,715,183 +804,720	+88%	+$23.1M	0.43%	26
2018 Q4	$19.4M	Buy	910,463 +517,241	+132%	+$13.3M	0.16%	33
2018 Q3	$15.6M	Hold	393,222	–	–	0.1%	47
2018 Q2	$15M	Hold	393,222	–	–	0.11%	49
2018 Q1	$11.8M	Buy	+393,222	New	+$13.3M	0.1%	50

Baker Bros. Advisors's BOLD Position: Q1 2020 in Review

Baker Bros. Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 804,720 shares — an estimated $48.2M sold.

Baker Bros. Advisors first reported a position in BOLD in Q1 2018 and held it in 8 quarters. The position peaked at $66.9M in Q1 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Baker Bros. Advisors reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Baker Bros. Advisors sold 804,720 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $48.2M.
Baker Bros. Advisors first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 8 quarters.
Baker Bros. Advisors's Audentes Therapeutics, Inc position peaked at $66.9M in Q1 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.